Aoxing Pharmaceutical Company Inc. Reports Enrollment Progress on Phase III Clinical Trial of TJSL Capsules

NEW YORK, NY--(Marketwire - July 19, 2010) - Aoxing Pharmaceutical Company, Inc. (NYSE Amex: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing and distribution of narcotic and pain-management products, today announced the Company has enrolled over 120 patients in its on-going Phase III clinical studies of oral TJSL Capsules, a novel investigational drug to treat primary dysmenorrhea ("PD"), or menstrual pain, in adult women. The enrollment process is ahead of schedule, targeting 440 patients, and now expected to be completed by December 2010.

Aoxing Pharma initiated this Phase III program in March 2010, following the successful completion of Phase II trial in January 2010. Phase II trial demonstrated that the investigational TJSL Capsules were safe and efficacious among 240 patients with primary dysmenorrheal during the 12-week, multi-center, randomized, double-blind and placebo-controlled trial.

The current Phase III clinical study is a 12-week, multi-center, randomized, double-blind and active-controlled study to evaluate the safety and efficacy of TJSL Capsules among 440 patients with primary dysmenorrheal. Subjects between 18 and 35 years old are actively being enrolled at six leading university teaching hospitals in metropolitan areas of China. Subjects receive TJSL Capsules or active control, three times a day for ten days, starting one week prior to each menstrual cycle or period. The primary endpoints used to evaluate efficacy is the sum of pain score differences, measured by visual analogue scale ("VAS"), as well as symptom improvement during menstruation over three menstrual cycles. This is a non-inferiority registration trial to the controlled arm, which was pre-approved by the China SFDA.

"We are very thrilled to report the swift progress of our Phase III clinical trial as it advances TJSL Capsules one step closer to becoming a potential new treatment option for patients with primary dysmenorrheal," said Zhenjiang Yue, the Chairman and CEO of Aoxing Pharma. "Extensive preclinical and clinical experience with TJSL Capsules suggests this drug holds a promising novel approach for the treatment of primary dysmenorrheal, a market estimated at $3 billion per year in China."

About Primary Dysmenorrhea ("PD")

Primary dysmenorrhea is defined as recurrent, cramping pain in the lower abdomen occurring just before or during menstruation, in the absence of demonstrable pelvic disease, such as endometriosis. Prevalence rates are as high as 90 percent. Initial presentation of PD typically occurs in adolescence. It is a common cause of absenteeism and reduced quality of life in women. Women with PD have increased production of endometrial prostaglandin, resulting in increased uterine tone and stronger, more frequent uterine contractions.

Pharmacological interventions available in the market include non-steroidal anti-inflammatory drugs (NSAIDs), hormomal contraceptives, levonorgestrel intrauterine contraception and tocolytics.

About TJSL Capsules

TJSL Capsules was originated by Professor X. Tian, a well known gynecologist in China. The drug is composed of several herbal medicines optimized based on her 40 years of medical research in treating PD. The drug has been used empirically by over 1,000 patients who suffered from PD. From in vivo studies, the drug was capable of reversing the effects of endometrial prostaglandin, reducing the frequency and strength of uterine contraction as well as providing pain relief.

About Aoxing Pharmaceutical Company, Inc.

Aoxing Pharmaceutical Company, Inc. is a US incorporated specialty pharmaceutical company with its main operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing has the largest and most advanced manufacturing facility in China for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China State Food and Drug Administration (SFDA). It has a joint venture collaboration with Johnson Matthey Plc to produce and market narcotics and neurological drugs in China. It also has strategic alliance partnership with QRxPharma, Phoenix PharmaLabs, Inc and American Oriental Bioengineering, Inc. For more information, please visit: www.aoxingpharma.com.

Safe Harbor Statement from Aoxing Pharmaceutical Company, Inc

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other risk factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended June 30, 2009, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.


Investor Relations Contact:
Brian Korb
Vice President
The Troup Group LLC
Tel: +1 646 378 2923
Email: bkorb@troutgroup.com

Back to news